

NYDFS USES NEW POWERS TO INVESTIGATE ALLEGED PRICE SPIKES IN COVID-19 MEDICINES, WHERE TARGETED PHARMA MANUFACTURERS ARE NOT NYDFS LICENSEES

Continuing its focus on consumer protection enforcement, the New York State Department of Financial Services (“DFS”) recently announced an investigation into alleged price spikes for six drugs connected to treatments of COVID-19 medical conditions.